Meeting
2017 ASCO Annual Meeting
A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.
Authors
Hope S. Rugo
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
Hope S. Rugo , Fabrice Andre , Gabor Rubovszky , Bella Kaufman , Kenichi Inoue , Masato Takahashi , Satoru Shimizu , Eva M. Ciruelos , Mario Campone , Pier Franco Conte , Hiroji Iwata , Sibylle Loibl , Ingrid A. Mayer , Dejan Juric , Anne-Sophie Longin , David Mills , Celine Wilke , Dalila B. Sellami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02437318
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS1111)
DOI
10.1200/JCO.2017.35.15_suppl.TPS1111
Abstract #
TPS1111
Poster Bd #
100b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.
First Author: Fabrice Andre
First Author: Cristina I. Truica
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
First Author: Michelino De Laurentiis